## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

_			
Vashington,	D.C.	20549	

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Chen Shu-Chih</u>				2. Issuer Name and Ticker or Trading Symbol ATOSSA THERAPEUTICS, INC. [ ATOS ]						ck all applica	ionship of Reportin all applicable) Director		on(s) to Issue			
(Last)	`	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/04/2023						Officer ( below)	(give title		Other (sp below)	pecify	
C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person						
(Street) SEATTL	E W	/A	98104									Form fil Person		e than	One Report	ing
(City)	(S	tate)	(Zip)	F	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						satisfy					
		Та	ble I - Non-D	erivati	ve Se	ecurities	s Acc	quired, D	isposed o	of, or Be	neficially	Owned				
Date				saction ZA. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		ed (A) or str. 3, 4 and 5	Beneficia Owned Fo	Form (D) o		n: Direct II or Indirect E nstr. 4) C	7. Nature of ndirect Beneficial Dwnership			
								Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise (Instr. 3)  3. Transaction Date Execution Date, if any (Month/Day/Year)  3A. Deemed Execution Date, if any (Month/Day/Year)		Code	ransaction Derivative ode (Instr. Securities		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	nt (Instr. 4)				
Stock Option (right to buy)	\$0.662	05/04/2023		A		125,000		(1)	05/04/2033	Common Stock	125,000	\$0	125,00	00	D	

## Explanation of Responses:

1. The options shall vest on a quarterly basis over the next 12 months. The options were issued at approximately 9:50 a.m. (ET) on May 4, 2023, with an exercise price of \$0.662, representing the most recently reported closing stock price on May 3, 2023.

/s/ Shu-Chih Chen, Ph.D.

05/05/2023

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.